Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Non-cash Items: 2023-2025

Historic Non-cash Items for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $10.1 million.

  • NewAmsterdam Pharma Co N.V's Non-cash Items rose 29.16% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 29.16%. This contributed to the annual value of $298.0 million for FY2024, which is 486.62% up from last year.
  • NewAmsterdam Pharma Co N.V's Non-cash Items amounted to $10.1 million in Q3 2025, which was down 92.84% from $141.1 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Non-cash Items high stood at $298.0 million for Q4 2024, and its period low was -$14,910 during Q2 2023.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's Non-cash Items averaged around $74.7 million, with its median value being $8.9 million (2025).
  • Its Non-cash Items has fluctuated over the past 5 years, first spiked by 1,310,623.14% in 2024, then fell by 27.80% in 2025.
  • Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Non-cash Items stood at $5.2 million in 2023, then spiked by 5,596.88% to $298.0 million in 2024, then rose by 29.16% to $10.1 million in 2025.
  • Its Non-cash Items stands at $10.1 million for Q3 2025, versus $141.1 million for Q2 2025 and $8.9 million for Q1 2025.